Ethyreal Bio emerges with $101M to challenge Amgen’s Tepezza in thyroid eye disease on June 10, 2026 Amgen Amgen 's anti-TSHR antibody Avoro Capital Cervical Atlas Ethyreal Bio Graves Disease Tepezza Thyroid associated opthalmopathies venture +